Atyr PHARMA (ATYR) Projected to Post Earnings on Thursday

Atyr PHARMA (NASDAQ:ATYR) will likely be posting its Q1 2025 quarterly earnings results before the market opens on Thursday, May 1st. Analysts expect Atyr PHARMA to post earnings of ($0.19) per share for the quarter.

Atyr PHARMA (NASDAQ:ATYR) last announced its quarterly earnings data on Thursday, March 13th. The company reported ($0.18) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.05. On average, analysts expect Atyr PHARMA to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Atyr PHARMA Trading Down 2.4 %

Atyr PHARMA stock opened at $3.27 on Tuesday. The company has a quick ratio of 5.41, a current ratio of 5.41 and a debt-to-equity ratio of 0.02. The firm has a 50-day moving average price of $3.35 and a two-hundred day moving average price of $3.38. The firm has a market capitalization of $290.57 million, a price-to-earnings ratio of -3.48 and a beta of 0.95. Atyr PHARMA has a 52-week low of $1.42 and a 52-week high of $4.66.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on the stock. Leerink Partners assumed coverage on shares of Atyr PHARMA in a research note on Tuesday, February 18th. They set an “outperform” rating and a $16.00 target price for the company. Cantor Fitzgerald began coverage on shares of Atyr PHARMA in a research note on Monday, January 6th. They issued an “overweight” rating for the company. HC Wainwright reaffirmed a “buy” rating and issued a $35.00 price target on shares of Atyr PHARMA in a research note on Friday, March 14th. Finally, Leerink Partnrs raised shares of Atyr PHARMA to a “strong-buy” rating in a research note on Tuesday, February 18th. Six equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, Atyr PHARMA presently has a consensus rating of “Buy” and a consensus target price of $18.60.

Atyr PHARMA Company Profile

aTyr Pharma, Inc engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.